RATIONALE: While the effects of d-amphetamine in increasing performance have been established, there is a paucity of information on the effects of methamphetamine on cognition in drug-naive subjects, and no published information on the effects of intravenous methamphetamine administration in dependent individuals. The dihydropyridine-class calcium channel antagonist, isradipine, has been posited as a putative treatment to prevent methamphetamine-associated hypertensive crisis and its sequelae. Yet, isradipine's effects on cognitive performance in methamphetamine-dependent individuals are not known. OBJECTIVE: Since individuals whose dependence on methamphetamine is attributable to the need to enhance performance may be loath to take a cognition-impairing medication, even for the treatment of life-threatening hypertensive crisis, it would be important to determine isradipine's effects on performance. METHODS: We therefore examined in a blinded, placebo-controlled, crossover design the cognitive effects of low and high doses of intravenous methamphetamine (15 mg and 30 mg, respectively) in both the presence and absence of isradipine. RESULTS:Intravenous d-methamphetamine produced dose-dependent increases in attention, concentration, and psychomotor performance. Isradipine, both with and without methamphetamine, had a modest effect to decrease attention. CONCLUSION: Our results do not support the further testing of isradipine as a medication for improving the cognitive impairments that have been associated with chronic methamphetamine use.
RCT Entities:
RATIONALE: While the effects of d-amphetamine in increasing performance have been established, there is a paucity of information on the effects of methamphetamine on cognition in drug-naive subjects, and no published information on the effects of intravenous methamphetamine administration in dependent individuals. The dihydropyridine-class calcium channel antagonist, isradipine, has been posited as a putative treatment to prevent methamphetamine-associated hypertensive crisis and its sequelae. Yet, isradipine's effects on cognitive performance in methamphetamine-dependent individuals are not known. OBJECTIVE: Since individuals whose dependence on methamphetamine is attributable to the need to enhance performance may be loath to take a cognition-impairing medication, even for the treatment of life-threatening hypertensive crisis, it would be important to determine isradipine's effects on performance. METHODS: We therefore examined in a blinded, placebo-controlled, crossover design the cognitive effects of low and high doses of intravenous methamphetamine (15 mg and 30 mg, respectively) in both the presence and absence of isradipine. RESULTS: Intravenous d-methamphetamine produced dose-dependent increases in attention, concentration, and psychomotor performance. Isradipine, both with and without methamphetamine, had a modest effect to decrease attention. CONCLUSION: Our results do not support the further testing of isradipine as a medication for improving the cognitive impairments that have been associated with chronic methamphetamine use.
Authors: J Quevedo; M Vianna; D Daroit; A G Born; C R Kuyven; R Roesler; J A Quillfeldt Journal: Neurobiol Learn Mem Date: 1998-05 Impact factor: 2.877
Authors: A Levy; R M Kong; M J Stillman; B Shukitt-Hale; T Kadar; T M Rauch; H R Lieberman Journal: Pharmacol Biochem Behav Date: 1991-07 Impact factor: 3.533
Authors: Bankole A Johnson; John D Roache; Nassima Ait-Daoud; Lynda T Wells; Christopher L Wallace; Michael A Dawes; Lei Liu; Xin-Qun Wang Journal: Prog Neuropsychopharmacol Biol Psychiatry Date: 2006-09-15 Impact factor: 5.067
Authors: Alasdair M Barr; William J Panenka; G William MacEwan; Allen E Thornton; Donna J Lang; William G Honer; Tania Lecomte Journal: J Psychiatry Neurosci Date: 2006-09 Impact factor: 6.186
Authors: J Cobb Scott; Steven Paul Woods; Georg E Matt; Rachel A Meyer; Robert K Heaton; J Hampton Atkinson; Igor Grant Journal: Neuropsychol Rev Date: 2007-09 Impact factor: 7.444
Authors: Patrick Recinto; Anjali Rose H Samant; Gustavo Chavez; Airee Kim; Clara J Yuan; Matthew Soleiman; Yanabel Grant; Scott Edwards; Sunmee Wee; George F Koob; Olivier George; Chitra D Mandyam Journal: Neuropsychopharmacology Date: 2011-12-28 Impact factor: 7.853
Authors: James J Mahoney; Brian J Jackson; Ari D Kalechstein; Richard De La Garza; Thomas F Newton Journal: Prog Neuropsychopharmacol Biol Psychiatry Date: 2010-11-29 Impact factor: 5.067
Authors: Carl L Hart; Erik W Gunderson; Audrey Perez; Matthew G Kirkpatrick; Andrew Thurmond; Sandra D Comer; Richard W Foltin Journal: Neuropsychopharmacology Date: 2007-09-12 Impact factor: 7.853